| Defining distinct features of anti-MOG antibody associated central nervous system demyelination |
32 |
| Danger signals in stroke and their role on microglia activation after ischemia |
26 |
| Treatment of glioblastoma in adults |
24 |
| Neurological complications of immune checkpoint inhibitors: what happens when you take the brakes off' the immune system |
24 |
| Clinical and electrophysiological impact of repetitive low-frequency transcranial magnetic stimulation on the sensory-motor network in patients with restless legs syndrome |
21 |
| Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy |
20 |
| Repetitive transcranial magnetic stimulation in stroke rehabilitation: review of the current evidence and pitfalls |
19 |
| Inflammatory molecules might become both biomarkers and therapeutic targets for stroke management |
19 |
| Ocrelizumab: a new milestone in multiple sclerosis therapy |
17 |
| Antisense oligonucleotides in neurological disorders |
16 |
| Advances in spinal muscular atrophy therapeutics |
15 |
| Risks and risk management in modern multiple sclerosis immunotherapeutic treatment |
15 |
| Ischemia-reperfusion injury in stroke: impact of the brain barriers and brain immune privilege on neutrophil function |
15 |
| Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study |
14 |
| An update on best practice of deep brain stimulation in Parkinson's disease |
14 |
| Pulsed immune reconstitution therapy in multiple sclerosis |
14 |
| Choices for long-term hypertensive control in patients after first-ever hemorrhagic stroke: a nationwide cohort study |
14 |
| Recent advances in treatment for narcolepsy |
13 |
| When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies |
13 |
| Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers |
13 |
| Primary angiitis of the central nervous system: diagnosis and treatment |
12 |
| Evolution of clinical trials in multiple sclerosis |
12 |
| Progressive multiple sclerosis: latest therapeutic developments and future directions |
12 |
| Understanding the burden of refractory myasthenia gravis |
11 |
| Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-beta 1a-treated multiple sclerosis |
11 |
| B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets |
10 |
| New developments in brain metastases |
10 |
| Advances in spinal cord imaging in multiple sclerosis |
10 |
| Primary central nervous system lymphoma |
9 |
| Imaging in neuro-oncology |
9 |
| Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment |
9 |
| Cerebral blood flow and cerebrovascular reactivity correlate with severity of motor symptoms in Parkinson's disease |
9 |
| Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis |
9 |
| Immunological and non-immunological effects of stem cell-derived extracellular vesicles on the ischaemic brain |
8 |
| Can inflammation be resolved in Alzheimer's disease? |
8 |
| Human induced pluripotent stem cell models for the study and treatment of Duchenne and Becker muscular dystrophies |
8 |
| Embolic strokes of undetermined source: theoretical construct or useful clinical tool? |
8 |
| Advances in brain imaging in multiple sclerosis |
8 |
| Anti-inflammatory treatments for stroke: from bench to bedside |
8 |
| Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience |
7 |
| Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure |
7 |
| Successful therapy with rituximab in three patients with probable neurosarcoidosis |
7 |
| Radiomics: a novel feature extraction method for brain neuron degeneration disease using F-18-FDG PET imaging and its implementation for Alzheimer's disease and mild cognitive impairment |
7 |
| The meningeal and choroidal infiltration routes for leukocytes in stroke |
6 |
| Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course |
6 |
| Postherpes simplex encephalitis: a case series of viral-triggered autoimmunity, synaptic autoantibodies and response to therapy |
6 |
| The monoclonal antibody GNbAC1: targeting human endogenous retroviruses in multiple sclerosis |
5 |
| Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age |
5 |
| Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: towards clinical integration? |
5 |
| Therapeutic effect on experimental acute cerebral infarction is enhanced after nanoceria labeling of human umbilical cord mesenchymal stem cells |
5 |
